What is meloxicam used for?

meloxicam is evaluated for the following indications with varying evidence strength: Anti-aging and longevity (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of meloxicam?

Common side effects of meloxicam (≥ 1 in 100): Dyspepsia and epigastric pain, Nausea, Headache and dizziness, Rash, Oedema. See the Safety section for uncommon and serious reactions.

Who should not take meloxicam?

meloxicam is contraindicated in: Hypersensitivity to meloxicam; Asthma, urticaria or other reactions to aspirin or NSAIDs; Active peptic ulcer or GI bleeding; Severe heart failure; Third trimester of pregnancy. Full list in the Safety section.

FDA category C. FDA Category C in the first and second trimester, D in the third. AEMPS contraindicates NSAIDs in the second half of pregnancy due to risk of premature closure of fetal ductus arteriosus, oligohydramnios and fetal-neonatal renal failure. SEGO prefers paracetamol for analgesia in pregnancy.

Anti-aging and longevity

Not recommended

Meloxicam is an NSAID with preferential COX-2 selectivity. It is prescribed for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis (AEMPS Ficha Técnica). In anti-aging regimens, meloxicam is used as a mild NSAID for long-term use in age-related joint pain. Regular use in people without confirmed osteoarthritis or other inflammatory pathology is not justified: 2020 and 2023 recommend non-pharmacological approaches (weight loss, exercise, physiotherapy) as the basis for joint complaints, with NSAIDs reserved for short flare courses. Meloxicam's COX-2 selectivity is incomplete and decreases at higher doses. The drug carries specific risks: gastrointestinal bleeding, blood-pressure elevation, acute kidney injury, and cardiovascular events. If meloxicam was prescribed for chronic use in age-related joint pain, consider seeking a second opinion.

Major

Apixaban

Direct oral anticoagulants (factor Xa inhibitors)

Mechanism

Apixaban is a direct factor Xa inhibitor; meloxicam blocks platelet function and injures the GI mucosa. Additive GI bleeding risk increases 2- to 3-fold.

Symptoms

Black or tarry stools (melena), vomiting blood or coffee-ground material, epigastric pain. Risk multiplies in older patients and with prior peptic ulcer disease.

Management

Avoid prolonged combination. If meloxicam is needed for a short course, use the minimum effective dose for 5–7 days with pantoprazole cover. For chronic analgesia: paracetamol or celecoxib.

Sources

FDA: Eliquis (apixaban) prescribing information (2014)

Pair details →

Major

Iopromide

X-ray contrast media. Watersoluble nephrotropic low-osmolar iodinated agents

Mechanism

Similar to iopromide + naproxen. Contrast and NSAID – additive nephrotoxicity.

Symptoms

Reduced urine output, rising creatinine and potassium, oedema. Symptoms appear earlier in older patients and chronic kidney disease.

Management

Stop meloxicam 48 hours before planned contrast and resume 48 hours after with stable renal function. Alternative analgesic: paracetamol. Provide contrast nephroprotection with adequate hydration.

Sources

FDA: Mobic (meloxicam) prescribing information (2012)

Pair details →

Major

Ketorolac

Non-steroidal anti-inflammatory drugs (NSAIDs)

Mechanism

Dual NSAID therapy – additive GI bleeding and nephrotoxicity risk. Despite meloxicam's preferential COX-2 selectivity, GI toxicity adds up when combined with ketorolac.

Symptoms

Black or tarry stools, vomiting blood, epigastric pain. Risk multiplies in older patients and with prior peptic ulcer disease.

Management

The combination is not prescribed. One NSAID at a time. Ketorolac courses no more than 5 days. For enhanced analgesia: paracetamol or a short opioid.

Sources

FDA: Toradol (ketorolac) boxed warning (2013)

Pair details →

Major

Methotrexate

Antimetabolites, folic acid analogues

Mechanism

NSAIDs reduce renal methotrexate clearance. At high oncologic doses: myelosuppression and mucositis. At low rheumatologic doses, risk is smaller but monitoring is needed.

Symptoms

Stomatitis, diarrhoea, falling leukocyte, platelet, and erythrocyte counts. Severe cases: fatal pancytopenia, nephrotoxicity.

Management

At oncologic methotrexate doses, the combination is not prescribed. At low rheumatologic doses, meloxicam is acceptable for a short course with blood count and creatinine monitoring every 1–3 months.

Sources

FDA: Methotrexate Sodium Tablets prescribing information (2016)

Pair details →

Major

Rivaroxaban

Direct oral anticoagulants (factor Xa inhibitors)

Mechanism

Direct oral anticoagulant (rivaroxaban) + NSAID (meloxicam) – additive GI bleeding risk via combined anticoagulation, mucosal injury, and platelet dysfunction.

Symptoms

Black or tarry stools, vomiting blood, epigastric pain. Risk multiplies in older patients and with prior peptic ulcer disease.

Management

Avoid prolonged combination. If meloxicam is needed for a short course, use the minimum effective dose for 5–7 days under pantoprazole cover. For chronic analgesia: paracetamol or celecoxib.

Sources

FDA: Xarelto (rivaroxaban) prescribing information (2019)

Pair details →

Major

tacrolimus

Calcineurin inhibitor (immunosuppressant)

Mechanism

NSAID (meloxicam) + nephrotoxic calcineurin inhibitor (tacrolimus) – additive acute kidney injury risk in transplant patients.

Symptoms

Reduced urine output, rising creatinine and potassium, oedema. Symptoms appear earlier in older patients and chronic kidney disease.

Management

Avoid prolonged combination. For post-transplant analgesia: paracetamol (up to 2 g/day) or a short opioid course. For neuropathic pain: gabapentin or pregabalin.

Sources

FDA: Prograf (tacrolimus) prescribing information (2013)

Pair details →

Major

Warfarin

Vitamin K antagonist anticoagulants

Mechanism

Meloxicam (preferential COX-2 NSAID) inhibits platelet aggregation less than non-selective NSAIDs but still injures the gastric mucosa. On warfarin, bleeding risk rises moderately.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.

Management

When unavoidable, use the minimum effective meloxicam dose for short courses under pantoprazole cover. Check INR at 1 week. For chronic needs, celecoxib or paracetamol are preferable.

Sources

FDA: Mobic (meloxicam) section 7 (2012)

Pair details →

Moderate

Acetylsalicylic acid

Antiplatelet agents (low dose) / NSAIDs (analgesic dose)

Mechanism

Meloxicam is preferentially COX-2 selective and weakly displaces aspirin from COX-1. Additive GI bleeding risk persists from the ulcerogenic effect of both drugs.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, black or tarry stools. Severe cases: GI bleeding.

Management

Aspirin's cardioprotective effect is preserved better than with ibuprofen/naproxen. PPI cover with pantoprazole is mandatory in chronic meloxicam therapy. Alternative analgesic: paracetamol or celecoxib.

Sources

FDA: Mobic (meloxicam) prescribing information (2012)

Pair details →

Moderate

Amlodipine

Calcium channel blockers (dihydropyridines)

Mechanism

NSAIDs antagonise amlodipine's antihypertensive effect via renal prostaglandin-dependent sodium regulation suppression.

Symptoms

Gradual blood pressure rise 1–2 weeks after starting meloxicam. In chronic kidney disease: fluid retention and oedema risk.

Management

For short meloxicam courses (5–7 days), monitor blood pressure. For chronic analgesia: switch to paracetamol or celecoxib (with PPI cover).

Sources

FDA: Mobic (meloxicam) prescribing information (2012)

Pair details →

Moderate

Bisoprolol

Selective beta-adrenergic blockers

Mechanism

NSAIDs weaken the antihypertensive effect of beta-blockers. Meloxicam is less ulcerogenic than non-selective NSAIDs (preferential COX-2 activity), but the renal effect persists.

Symptoms

Gradual blood pressure rise 1–2 weeks after starting the NSAID. In chronic kidney disease: risk of fluid retention and oedema.

Management

For short meloxicam courses (5–7 days), monitor blood pressure. For chronic analgesia: switch to paracetamol or celecoxib (with PPI cover).

Sources

FDA: Mobic (meloxicam) prescribing information (2012)

Pair details →

Contraindications

Hypersensitivity to meloxicam
Asthma, urticaria or other reactions to aspirin or NSAIDs
Active peptic ulcer or GI bleeding
Severe heart failure
Third trimester of pregnancy
Severe hepatic or renal impairment

Serious adverse effects

GI bleeding and perforation
Cardiovascular events (MI, stroke)
Acute kidney injury
Severe cutaneous reactions (Stevens-Johnson)
Hepatotoxicity

Common adverse effects

Dyspepsia and epigastric pain
Nausea
Headache and dizziness
Rash
Oedema

PregnancyFDA C

FDA Category C in the first and second trimester, D in the third. AEMPS contraindicates NSAIDs in the second half of pregnancy due to risk of premature closure of fetal ductus arteriosus, oligohydramnios and fetal-neonatal renal failure. SEGO prefers paracetamol for analgesia in pregnancy.

Breastfeeding

Compatible. Hale L3. Human milk transfer data are limited; animal data show minimal transfer. Ibuprofen is the first-line NSAID in breastfeeding; meloxicam is second-line.

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

meloxicam

Mechanism of action

Marketing claims without evidence base

Anti-aging and longevity

Drug–drug interactions

Apixaban

Iopromide

Ketorolac

Methotrexate

Rivaroxaban

tacrolimus

Warfarin

Acetylsalicylic acid

Amlodipine

Bisoprolol

Check interaction with another drug

Official sources

Safety

Contraindications

Serious adverse effects

Common adverse effects

PregnancyFDA C

Breastfeeding

Frequently asked